AMGEN Inc
NASDAQ: AMGN
$337.38
+$1.43 (+0.4%)
Closing Price on September 20, 2024
AMGN Articles
In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit the tape.
Published:
Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would like to see several competing biotechs join in on the fun.
Published:
ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company or sector, or in the case of...
Published:
ThinkstockAs the summer starts, a large agenda is out there for investors when it comes to top biotech and specialty pharmaceutical companies making announcements and presenting clinical data. The...
Published:
Google topped all companies in terms of best pay and benefits in a new survey by online jobs site Glassdoor. The list was thick with tech and biotech companies.
Published:
ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many of...
Published:
ThinkstockBy any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue...
Published:
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild card report...
Published:
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after years of...
Published:
Thinkstock24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many of...
Published:
Amgen submitted an SEC Filing showing that, as of April 1, one of its subsidiaries and a GlaxoSmithKline subsidiary have terminated part and amended part of a collaboration agreement from 2009.
Published:
Jon OggMost investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs...
Published:
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top names rated Outperform...
Published:
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, March 27, 2014. They include Apple, BlackBerry, Chesapeake Energy, Citigroup and King...
Published: